MedTrace Logo

Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant

NCT03850418 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 43

Last updated 2026-02-24

No results posted yet for this study

Summary

Previous studies provide a rationale for administration of AZA after allo SCT for decreasing chimerism. The investigators hypothesize that azacitidine can be well tolerated after SCT and help decrease rate of decreasing donor chimerism and hence decrease relapse without increasing GVHD

Conditions

  • Myeloid Malignancy

Interventions

DRUG

azacitidine

azacitidine 32mg/m2 x 5 days every 28 days for minimum of 4 cycles if tolerated

Sponsors & Collaborators

  • Henry Ford Health System

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-07-01
Primary Completion
2028-02-20
Completion
2028-02-20
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03850418 on ClinicalTrials.gov